JAKAFI
LOE ApproachingNDAORALTABLETPriority Review
Approved
Nov 2011
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
6/8 — Strong
Priority Review
JAKAFI by Incyte is ruxolitinib, a kinase inhibitor, inhibits janus associated kinases (jaks), jak1 and jak2, which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Approved for intermediate, high-risk myelofibrosis (mf), including primary mf and 7 more indications. First approved in 2011.
Drug data last refreshed 19h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JAKAFI (ruxolitinib) is an oral Janus Kinase (JAK) inhibitor approved in 2011 for hematologic malignancies and inflammatory conditions. It works by selectively inhibiting JAK1 and JAK2 signaling pathways to reduce abnormal cell proliferation and inflammatory responses. The drug represents a foundational kinase inhibitor class with broad mechanistic applicability across multiple disease areas.
$1.9BPart D
LOE Approaching2.4 years to LOEMature revenue base nearing patent expiration (2028) signals transition from growth to defense mode, with smaller specialized teams focused on lifecycle extension and label retention.
Mechanism of Action
Ruxolitinib, a kinase inhibitor, inhibits Janus Associated Kinases (JAKs), JAK1 and JAK2, which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. JAK signaling involves recruitment of STATs (signal transducers and activators…
Indications (10)
Worked on JAKAFI at Incyte? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.